Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr 8;16(4):e0249644.
doi: 10.1371/journal.pone.0249644. eCollection 2021.

Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh

Reaz Mahmud  1 , Md Mujibur Rahman  2 , Mohammad Aftab Rassel  1 , Farhana Binte Monayem  3 , S K Jakaria Been Sayeed  2 , Md Shahidul Islam  3 , Mohammed Monirul Islam  4
Affiliations
Clinical Trial

Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh

Reaz Mahmud et al. PLoS One. .

Abstract

Background: Post-coronavirus disease (COVID-19) syndrome includes persistence of symptoms beyond viral clearance and fresh development of symptoms or exaggeration of chronic diseases within a month after initial clinical and virological cure of the disease with a viral etiology. We aimed to determine the incidence, association, and risk factors associated with development of the post-COVID-19 syndrome.

Methods: We conducted a prospective cohort study at Dhaka Medical College Hospital between June 01, 2020 and August 10, 2020. All the enrolled patients were followed up for a month after clinical improvement, which was defined according the World Health Organization and Bangladesh guidelines as normal body temperature for successive 3 days, significant improvement in respiratory symptoms (respiratory rate <25/breath/minute with no dyspnea), and oxygen saturation >93% without assisted oxygen inhalation.

Findings: Among the 400 recruited patients, 355 patients were analyzed. In total, 46% patients developed post-COVID-19 symptoms, with post-viral fatigue being the most prevalent symptom in 70% cases. The post-COVID-19 syndrome was associated with female gender (relative risk [RR]: 1.2, 95% confidence interval [CI]: 1.02-1.48, p = 0.03), those who required a prolonged time for clinical improvement (p<0.001), and those showing COVID-19 positivity after 14 days (RR: 1.09, 95% CI: 1.00-1.19, p<0.001) of initial positivity. Patients with severe COVID-19 at presentation developed post-COVID-19 syndrome (p = 0.02). Patients with fever (RR: 1.5, 95% CI: 1.05-2.27, p = 0.03), cough (RR: 1.36, 95% CI: 1.02-1.81, p = 0.04), respiratory distress (RR: 1.3, 95% CI: 1.4-1.56, p = 0.001), and lethargy (RR: 1.2, 95% CI: 1.06-1.35, p = 0.003) as the presenting features were associated with the development of the more susceptible to develop post COVID-19 syndrome than the others. Logistic regression analysis revealed female sex, respiratory distress, lethargy, and long duration of the disease as risk factors.

Conclusion: Female sex, respiratory distress, lethargy, and long disease duration are critical risk factors for the development of post-COVID-19 syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Patient selection for this prospective cohort study.
Fig 2
Fig 2. Comparison of COVID-19 and post-COVID-19 symptoms.
See this image and copyright information in PMC

References

    1. World Health Organization. GCM teleconference–Note for the Records. 10 January 2020. Subject: Pneumonia in Wuhan, China. Available from: https://www.WHO.int/blueprint/10-01-2020-nfr-gcm.pdf?ua=. Accessed 22 september,2020.
    1. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutie´rrez-Ocampo E, Villamizar-Pen˜a R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020; 34:101623. 10.1016/j.tmaid.2020.101623 - DOI - PMC - PubMed
    1. Zheng KI, Feng G, Liu W‐Y, Targher G, Byrne CD, Zheng M‐H. Extrapulmonary complications of COVID‐19: A multisystem disease? J Med Virol. 2020; 1– 13. 10.1002/jmv.26294 - DOI - PMC - PubMed
    1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229):1033–4. 10.1016/S0140-6736(20)30628-0 - DOI - PMC - PubMed
    1. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020. September; 288(3):335–344. 10.1111/joim.13089 Epub 2020 Jun 17. ; PMCID: PMC7267446. - DOI - PMC - PubMed

Publication types